Advanced search×

Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.

Carmelo C Nucera, Matthew A MA Nehs, Sushruta S SS Nagarkatti, Peter M PM Sadow, Michal M Mekel, Andrew H AH Fischer, Paul S PS Lin, Gideon E GE Bollag, Jack J Lawler, Richard A RA Hodin, and Sareh S Parangi

Oncologist 16(3):296-309 (2011) PMID 21355020

B-Raf(V600E) may play a role in the progression from papillary thyroid cancer to anaplastic thyroid cancer (ATC). We tested the effects of a highly selective B-Raf(V600E) inhibitor, PLX4720, on proliferation, migration, and invasion both in human thyroid cancer cell lines (8505c(B-RafV600E) and TPC-1(RET/PTC-1 and wild-type B-Raf)) and in primary human normal thyroid (NT) follicular cells engineered with or without B-Raf(V600E).

DOI: 10.1634/theoncologist.2010-0317
Version: za2963e q8za8 q8zb6 q8zcd q8zdd q8ze1 q8zfb q8zg4
View PDF

Similar articles you may find interesting…

  1. Targeting BRAF in advanced melanoma: a first step toward manageable disease.
    Adina Vultur, Jessie Villanueva, and Meenhard Herlyn

    Clin Cancer Res 17(7):1658-63 (2011) PMID 21447722 PMCID PMC3079374

    Melanoma is the deadliest form of skin cancer and its incidence has been increasing worldwide. The disease manifests itself as clinically and genetically distinct subgroups, indicating the need for patient-specific diagnostic and treatment tools. The discovery of activating mutations...
    View PDF
  2. A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status.
    Marie C MC Zipser, Ossia M OM Eichhoff, ... Keith S KS Hoek

    Pigment Cell Res 24(2):326-33 (2011) PMID 21176117

    We investigated the effects of two different inhibitors of MAPK signaling in proliferative and invasive melanoma cell cultures with various mutations in the MAPK pathway. Proliferative melanoma cells were more susceptible to pathway inhibition than invasive phenotype cells, irrespective of BRAF muta...
    Buy PDF
  3. Somatic p16(INK4a) loss accelerates melanomagenesis.
    K B Monahan, G I Rozenberg, ... N E Sharpless

    Oncogene 29(43):5809-17 (2010) PMID 20697345

    We engineered a novel conditional p16(INK4a)-null allele and combined this allele with a melanocyte-specific, inducible CRE recombinase strain, a conditional p53-null allele and a loxP-stop-loxP activatable oncogenic K-Ras allele. We found potent synergy between melanocyte-specific activation of K-R...
    Buy PDF